As discussed above, in the framework of the ACH2.0, it is assumed that in the second, symptomatic AD stage, the bulk, or the entire output, of the AβPP-independent iAβ production pathway is not secreted but retained within the cell [1,2]; this stimulates and perpetuates its own production and thus drives the disease [1]. This evidence concerns the gene APP and Alzheimer disease.